|
|
 |
|
Viewing report
|
|
|
|
Product Profiles: Schizophrenia - Adjunctive treatments to carve new niche in mature market
Datamonitor, Oct 2011, Pages: 193
With the imminent loss of market exclusivity of key atypical antipsychotics Zyprexa (olanzapine; Eli Lilly) and Seroquel (quetiapine: AstraZeneca), schizophrenia pipeline therapies will launch into a competitive market. Datamonitor views the development of novel drugs and adjunctive therapies as an important strategy for success.
Features and benefits
- Access Datamonitor’s assessment of key marketed and pipeline drugs’ clinical and commercial attractiveness.
- Assessment of the strengths, weaknesses, opportunities and threats for marketed and late-stage pipeline candidates
- Analysis of the product positioning for each marketed agents within the schizophrenia market.
- Evaluate the latest clinical trial data for late-stage pipeline drugs and how they satisfy the unmet needs in schizophrenia
Highlights
In order to thrive in the schizophrenia environment, new therapies must be sufficiently differentiated from existing antipsychotics. Datamonitor believes developers of undifferentiated oral products will struggle to compete in this mature market because but will find position as second or later line of therapy for treatment refractory patients
Developing depot formulations is a key successful life-cycle management strategy in the schizophrenia market in order to protect franchises from generic erosion. Recent launches of monthly depots Zyprexa Relprevv and Invega Sustenna have helped Eli Lilly and Johnson & Johnson strengthen their position in this market.
The prospects for adjunctive therapies for hard-to-treat schizophrenia symptoms will be highly welcomed and will create a new niche in this mature market. Rather than compete with existing therapies, these drugs will complement generic formulations to partially combat generic erosion.
Your key questions answered
- Where will new adjunctive therapies be positioned?
- What strategies will developers implement upon generic erosion of their brands?
- Where will the new pipeline therapies fit into the treatment algorithm?
- What are the comparative strengths and weaknesses of the key schizophrenia brands and how do they compare to and pipeline candidates?
|
|
|
|
